*The following content is generated by AI and is for reference only.
Empagliflozin is a highly selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), primarily utilized in the management of type 2 diabetes mellitus. Its chemical identity is defined by the molecular formula C₂₃H₂₇ClO₉ and the CAS registry number 864055-71-8. Structurally, it belongs to the class of phlorizin derivatives, featuring a specific configuration that ensures potent binding to the SGLT2 protein located in the proximal convoluted tubules of the kidneys. Unlike other antidiabetic agents, Empagliflozin operates through a unique mechanism independent of insulin secretion or sensitivity. By blocking glucose reabsorption in the renal tubules, it facilitates the excretion of excess glucose into the urine, thereby effectively lowering blood glucose levels without inducing hypoglycemia when used as monotherapy. Beyond glycemic control, clinical trials have demonstrated significant cardiovascular benefits, including a reduced risk of major adverse cardiovascular events and hospitalization for heart failure. This dual action makes it a preferred choice for patients with type 2 diabetes who also suffer from established cardiovascular disease or high-risk factors. The drug is typically administered orally once daily, offering convenience and improved patient adherence. Common side effects may include genital mycotic infections due to increased urinary glucose concentration, though serious adverse events are rare. As a landmark therapy in modern endocrinology, Empagliflozin represents a paradigm shift towards organ protection, addressing not only hyperglycemia but also the systemic complications associated with metabolic syndrome. Its development underscores the importance of targeting renal mechanisms to achieve comprehensive metabolic regulation, solidifying its status as a cornerstone treatment in current clinical guidelines worldwide.